Using Urine Samples to Identify Lung Cancer

Study summary

The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and researchers think these chemicals can be used to identify people with lung cancer without the need for invasive procedures (like biopsy).

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedurine sample

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Diagnostic Test: urine sample

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC °Note: Single, monolateral nodule of at least 50% solid composition visible on a Chest CT scan that is suspicious for a primary neoplasm as confirmed by an official MSK radiologist read
Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC
Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and/or PET scan criteria

Reasons someone may not be able to joinExclusion criteria

Aged \<18 years
Lack of available results from low-dose CT
Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year
Pregnant (for women)
Taking drugs that affect the immune system
Chronic disease related to the immune system
Missing clinical data (i.e., current clinical staging)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)Commack, New York
Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 15, 2026. Always confirm current availability with the study team.

View original record ↗